Showing results (1-10 of 320) with videos related to
Sort By:
Pageof 32
Expert Opinion on Therapeutic Patents|August 24, 2013
AT1 antagonists: a patent review (2008 - 2012)Thomas Mavromoustakos, George Agelis, Serdar DurdagiJournal of Computer-Aided Molecular Design|July 13, 2010
An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT(1) angiotensin II receptor antagonist: reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studiesGeorge Agelis, Panagiota Roumelioti, Amalia Resvani, et al.European Journal of Medicinal Chemistry|November 11, 2011
An effort to discover the preferred conformation of the potent AMG3 cannabinoid analog when reaching the active sites of the cannabinoid receptorsSerdar Durdagi, Manthos G Papadopoulos, Thomas MavromoustakosBioorganic & Medicinal Chemistry Letters|October 28, 2008
3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitorsSerdar Durdagi, Thomas Mavromoustakos, Manthos G PapadopoulosEuropean Journal of Medicinal Chemistry|August 15, 2012
The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivativesGeorge Agelis, Amalia Resvani, Serdar Durdagi, et al.Bioorganic & Medicinal Chemistry|July 4, 2008
Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptorsSerdar Durdagi, Heribert Reis, Manthos G Papadopoulos, et al.Bioorganic & Medicinal Chemistry|November 11, 2008
Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulationsSerdar Durdagi, Thomas Mavromoustakos, Nikos Chronakis, et al.Bioorganic & Medicinal Chemistry Letters|November 6, 2007
Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activitySerdar Durdagi, Manthos G Papadopoulos, Demetris P Papahatjis, et al.Journal of Molecular Graphics & Modelling|September 22, 2010
Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studiesAggeliki Politi, Serdar Durdagi, Panagiota Moutevelis-Minakakis, et al.Journal of Chemical Information and Modeling|October 29, 2008
3D QSAR/CoMFA and CoMSIA studies on antileukemic steroidal esters coupled with conformationally flexible nitrogen mustardsAgnes Kapou, Nikolas-P Benetis, Serdar Durdagi, et al.Pageof 32